Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion

The antimetastatic ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlorouthenate (NAMI-A) is tested in the B16 melanoma model in vitro and in vivo. Treatment of B6D2F1 mice carrying intra-footpad B16 melanoma with 35 mg/kg/day NAMI-A for 6 days reduces metastasis weight independently of whether NAMI-A is given before or after surgical removal of the primary tumor. Metastasis reduction is unrelated to NAMI-A concentration, which is 10-fold lower than on primary site (1 versus 0.1 mM), and is correlated to the reduction of plasma gelatinolitic activity and to the decrease of cells expressing CD44, CD54, and integrin-β3 adhesion molecules. Metastatic cells also show the reduction of the S-phase cells with accumulation in the G0/G1 phase. In vitro, on the highly metastatic B16F10 cell line, NAMI-A reduces cell Matrigel invasion and its ability to cross a layer of endothelial cells after short exposure (1 h) to 1 to 100 μM concentrations. In these conditions, NAMI-A reduces the gelatinase activity of tumor cells, and it also increases cell adhesion to poly-l-lysine and, in particular, to fibronectin, and this effect is associated to the increase of F-actin condensation. This work shows the selective effectiveness of NAMI-A on the metastatic melanoma and suggests that metastasis inhibition is due to the negative modulation of tumor cell invasion processes, a mechanism in which the reduction of the gelatinolitic activity of tumor cells plays a crucial role.

[1]  D. Elder,et al.  Integrin Distribution in Malignant Melanoma : Association of the ß 3 Subunit with Tumor Progression 1 , 2006 .

[2]  G. Sava,et al.  Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[3]  K. Honn,et al.  Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix , 1992, Cancer and Metastasis Reviews.

[4]  A. Bergamo,et al.  Ruthenium antimetastatic agents. , 2004, Current topics in medicinal chemistry.

[5]  M. Bacac,et al.  Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells , 2004, Cancer Immunology, Immunotherapy.

[6]  G. Sava,et al.  Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. , 2004, European journal of cancer.

[7]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[8]  G. Sava,et al.  Primary Tumor, Lung and Kidney Retention and Antimetastasis Effect of NAMI-A Following Different Routes of Administration , 2003, Investigational New Drugs.

[9]  G. Sava,et al.  Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex , 1998, Clinical & Experimental Metastasis.

[10]  U. Puistola,et al.  Ovarian cancer cell invasion is inhibited by paclitaxel , 1997, Clinical & Experimental Metastasis.

[11]  Judith P. Johnson Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease , 1991, Cancer and Metastasis Reviews.

[12]  A. Bergamo,et al.  Ruthenium anticancer drugs. , 2004, Metal ions in biological systems.

[13]  G. Pezzoni,et al.  Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  F. Mannello Circulating 92‐kilodalton matrix metalloproteinase (MMP‐9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma , 2003, Cancer.

[15]  Bartek Rajwa,et al.  Comparison of daunomycin effects on human keratinocytes and melanoma HTB 1410 cells. Image cytometry study. , 2003, Anticancer Research.

[16]  E. Raso,et al.  Role for β3 integrins in human melanoma growth and survival , 2002 .

[17]  E. D. Bal de Kier Joffé,et al.  Circulating 92‐kilodalton matrix metalloproteinase (MMP‐9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma , 2002, Cancer.

[18]  A. Montgomery,et al.  Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. , 2001, Molecular biology of the cell.

[19]  J. Regezi,et al.  Integrin αvβ3 mediates K1735 murine melanoma cell motility in vivo and in vitro , 2001 .

[20]  A. Montgomery,et al.  Involvement of Integrin v 3 and Cell Adhesion Molecule L1 in Transendothelial Migration of Melanoma Cells , 2001 .

[21]  L. Schuchter,et al.  Metastatic melanoma , 2001, Current treatment options in oncology.

[22]  A. Bergamo,et al.  Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes. , 2000, The Journal of pharmacology and experimental therapeutics.

[23]  B. Hinz,et al.  Actin-dependent lamellipodia formation and microtubule-dependent tail retraction control-directed cell migration. , 2000, Molecular biology of the cell.

[24]  L. Matrisian,et al.  Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.

[25]  A. Bergamo,et al.  In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  A. Bergamo,et al.  Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine. , 1999, Anticancer research.

[27]  G. Sava,et al.  Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors. , 1999, Anti-cancer drugs.

[28]  A. Strongin,et al.  Matrix metalloproteinase-2 activation modulates glioma cell migration. , 1997, Journal of cell science.

[29]  T. Vu,et al.  Gelatinase A Activation Is Regulated by the Organization of the Polymerized Actin Cytoskeleton* , 1997, The Journal of Biological Chemistry.

[30]  J. E. Celis,et al.  Cell Biology: A Laboratory Handbook , 1997 .

[31]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[32]  W. Stetler-Stevenson,et al.  Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. , 1996, Cell.

[33]  R. Kerbel,et al.  The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. , 1995, Cancer research.

[34]  E. Danen,et al.  Emergence of α5β1 fibronectin‐ and αvβ3 vitronectin‐receptor expression in melanocytic tumour progression , 1994 .

[35]  E. Danen,et al.  Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. , 1994, Histopathology.

[36]  L. Liotta,et al.  Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. , 1992, Cancer research.

[37]  M. Stearns,et al.  Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. , 1992, Cancer research.

[38]  M. Hendrix,et al.  Role of the alpha v beta 3 integrin in human melanoma cell invasion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Nagase,et al.  Determination of ruthenium in biological tissue by graphite furnace AAS after decomposition of the sample by tetramethylammonium hydroxide. , 1992 .

[40]  I. Hart,et al.  Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. , 1991, Cancer research.

[41]  D. Elder,et al.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. , 1990, Cancer research.

[42]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[43]  M. Henn,et al.  New Ruthenium Complexes for the Treatment of Cancer , 1989 .

[44]  M. Clarke Ruthenium Chemistry Pertaining to the Design of Anticancer Agents , 1989 .